15-Patient Investigator-Initiated Phase 1 Study

Rui Therapeutics, a Chinese company also known as Nanjing Enrui Kerunuo Biotechnology, is conducting an early-stage clinical trial with Jiangsu Provincial People's Hospital, evaluating KN5501, a CD19-targeted allogeneic CAR-NK cell therapy. NCT06318533 is a single-arm, open-label Early Phase 1 study enrolling 15 patients with relapsed/refractory B-cell-mediated autoimmune diseases, primarily assessing safety and dose-limiting toxicity (DLT). Patients undergo lymphodepletion with fludarabine and cyclophosphamide, followed by KN5501 administration, with monitoring of cell persistence, B-cell depletion, and disease activity. A key aspect is the expansion of CAR-NK, traditionally focused on oncology, into an immune reset strategy for chronic autoimmune conditions.

KN5501: Product and Regulatory Status

KN5501 is an investigational cell therapy product, not yet branded, consisting of CD19-chimeric antigen receptor-modified NK cells derived from healthy donors, designed to eliminate CD19-positive B cells. Its off-the-shelf manufacturing approach may reduce turnaround time and manufacturing variability compared to autologous CAR-T therapies, which require patient-specific collection and production. Rui Therapeutics secured regulatory approval for the Phase 1 clinical trial of KN5501 from the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA) in September 2025. A subsequent registration study, NCT07358988, is a multi-center Phase 1 trial involving 36 patients with refractory systemic lupus erythematosus (SLE), with an anticipated start date in January 2026. Regulatory submissions to the FDA, EMA, and PMDA are not yet initiated, and the current asset value is largely dependent on early safety and pharmacokinetic data.

Competitive Landscape: Standard of Care and Cell Therapies

The current standard of care includes hydroxychloroquine, glucocorticoids, and mycophenolate, along with GSK's Benlysta (belimumab, a BAFF inhibitor) and AstraZeneca's Saphnelo (anifrolumab, a type I interferon receptor inhibitor). Benlysta received FDA approval for SLE in March 2011 and generated approximately $1.8 billion in sales in 2025, serving as a commercial benchmark in the market for repeatedly administered biologics. Saphnelo was approved by the FDA in August 2021. Both products primarily focus on disease control, while cell therapies aim for sustained remission without ongoing drug administration, representing a different value proposition. Direct competitors include Nkarta's (NKTX) CD19 CAR-NK therapy, NKX019, in a Phase 1/2 program, and Century Therapeutics' (IPSC) iPSC-derived CD19 CAR-NK therapy, CNTY-101, in a Phase 1 trial. Several autologous CD19 CAR-T clinical programs are also raising the efficacy bar.

Value of Early Data and Commercialization Challenges

Rui Therapeutics has reported that in a separate SLE study, four severely ill patients treated with KN5501 experienced improvement from severe to mild disease based on the SLEDAI-2K score, with related Chinese case data published in The Lancet in November 2025. However, the small sample size and lack of a randomized controlled trial mean that DLT, infection rates, cytokine release syndrome (CRS), neurotoxicity, and duration of remission will be critical determinants of investment decisions in NCT06318533. The global SLE treatment market is estimated at approximately $1.9 billion in 2024, and Benlysta's standalone sales of approximately $1.8 billion in 2025 demonstrate the unmet need and willingness to pay in severe patients. Consistent manufacturing, the need for repeat dosing, and the burden of lymphodepletion must be addressed for KN5501 to translate Chinese clinical results into a global regulatory strategy and licensing value.